Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

663 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Opat S, et al. Among authors: tedeschi a. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668. Blood Adv. 2023. PMID: 37682792 Free PMC article. Clinical Trial.
Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.
Tam CS, Trotman J, Opat S, Stern JC, Allewelt H, By K, Novotny W, Huang J, Tedeschi A. Tam CS, et al. Among authors: tedeschi a. Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990. Blood Adv. 2023. PMID: 36753605 Free PMC article. No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 39112228
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Jermain M, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Barr PM, et al. Among authors: tedeschi a. Future Oncol. 2023 Jan 9. doi: 10.2217/fon-2022-0898. Online ahead of print. Future Oncol. 2023. PMID: 36617990 Free article. Review.
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.
Zamprogna G, Frustaci AM, Travi G, Borella C, Reda G, Motta M, Deodato M, Bossi E, Mattiello V, Ferrari MB, Cotilli G, Gambacorti-Passerini C, Cairoli R, Puoti M, Tedeschi A. Zamprogna G, et al. Among authors: tedeschi a. Hemasphere. 2023 May 4;7(5):e880. doi: 10.1097/HS9.0000000000000880. eCollection 2023 May. Hemasphere. 2023. PMID: 37153871 Free PMC article. No abstract available.
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
Del Giudice I, Cappelli LV, Delgado J, Niemann CU, Andersen MA, Rotbain EHC, Aarup K, Walewska R, Visentin A, Deodato M, Frustaci AM, Cavalloni C, Gentile M, Yassin MA, Lad D, Scarfò L, Flogegard M, Mattsson M, Raponi S, Ilari C, Starza ID, Orlandi EM, Tedeschi A, Trentin L, Semenzato G, Guarini A, Ghia P, Montserrat E, Foà R. Del Giudice I, et al. Among authors: tedeschi a. Br J Haematol. 2023 Apr;201(2):353-356. doi: 10.1111/bjh.18696. Epub 2023 Feb 15. Br J Haematol. 2023. PMID: 36793194 Review. No abstract available.
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.
Innocenti I, Tomasso A, Giannarelli D, Scarfò L, Murru R, Visentin A, Frustaci AM, Morelli F, Vitale C, Mosca A, Sanna A, Farina G, Laureana R, Gentile M, Galitzia A, Pasquale R, Autore F, Olivieri J, Romeo A, Deodato M, Stirparo L, Corbingi A, Innao V, Perutelli F, Martini F, Sportoletti P, Fresa A, Del Principe MI, Tedeschi A, Coscia M, Ghia P, Laurenti L. Innocenti I, et al. Among authors: tedeschi a. Hematol Oncol. 2025 Jan;43(1):e70033. doi: 10.1002/hon.70033. Hematol Oncol. 2025. PMID: 39809722 No abstract available.
Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.
Gallucci G, Larocca M, Navazio A, Turazza FM, Inno A, Canale ML, Oliva S, Besutti G, Tedeschi A, Aschieri D, Russo A, Gori S, Silvestris N, Pinto C, Tarantini L. Gallucci G, et al. Among authors: tedeschi a. Int J Mol Sci. 2025 Jan 2;26(1):334. doi: 10.3390/ijms26010334. Int J Mol Sci. 2025. PMID: 39796190 Free PMC article. Review.
663 results